Thromboxane A2 (A2, Thromboxane)

An unstable intermediate between the prostaglandin endoperoxides and thromboxane B2. The compound has a bicyclic oxaneoxetane structure. It is a potent inducer of platelet aggregation and causes vasoconstriction. It is the principal component of rabbit aorta contracting substance (RCS).

Also Known As:

Networked: 1294 relevant articles (39 outcomes, 132 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Zhang, Jian X: 5 articles (12/2009 - 03/2003)
2.	Dogné, Jean-Michel: 5 articles (09/2009 - 01/2002)
3.	Huang, Run-Yue: 4 articles (01/2015 - 04/2011)
4.	Wu, Qiang: 3 articles (12/2015 - 04/2014)
5.	He, Guangwei: 3 articles (12/2015 - 04/2014)
6.	Fang, Weirong: 3 articles (12/2015 - 04/2014)
7.	Chu, Shaoxing: 3 articles (12/2015 - 04/2014)
8.	Li, Yunman: 3 articles (12/2015 - 04/2014)
9.	Violi, Francesco: 3 articles (10/2015 - 10/2004)
10.	Yalcin, Murat: 3 articles (05/2014 - 11/2006)

Related Diseases

1.	Thrombosis (Thrombus) 06/30/1989 - "This study suggests that males exposed to LPS may generate more thromboxane A2 than females and thus be at higher risk of developing thrombosis." 12/01/2015 - "Thromboxane A2 (TXA2) can induce the platelet aggregation and lead to thrombosis. " 08/15/2003 - "Thromboxane A2 (TXA2)-mediated platelet secretion and aggregation are important in thrombosis. " 01/01/1996 - "These observations thus suggest that microcirculatory disturbances by platelet thrombus, which are mediated by thromboxane A2 at least in part, play an important role in ETX-induced intestinal damage." 09/01/1991 - "The thromboxane A2 antagonist SQ29548 (100 mg/kg/min iv) resulted in a significant delay in platelet thrombus formation in arterioles and venules. "
2.	Ischemia 04/01/1993 - "Although previous studies have already documented the increased release of cardiac thromboxane A2 after ischemia, none have studied the effects of cardiac thromboxane A2 on hemodynamics. " 12/01/1990 - "Our previous studies demonstrated that the bilateral hindlimb ischemia/reperfusion stimulates thromboxane A2 (TXA2) production. " 12/01/1983 - "In this study, the thesis that ischemia of the limb is a significant stimulus to thromboxane A2 synthesis and the generation of a circulating negative inotrope is tested. " 09/01/1998 - "Suppression of cytokine production by thromboxane A2 inhibitor in liver ischemia." 07/01/1996 - "Thromboxane A2 accumulates in the hippocampus after global ischemia and may play a key role in postischemic hypoperfusion. "
3.	Pathologic Constriction (Stenosis) 04/01/1992 - "Even during hypoperfusion produced by a flow limiting arterial stenosis, the coronary resistance vessels remain responsive to the vasoconstrictor effect of thromboxane A2. " 04/01/1992 - "The aim was to test the hypothesis that thromboxane A2 can cause vasoconstriction of coronary resistance vessels during exercise in hypoperfused regions of myocardium distal to an arterial stenosis. " 12/01/1985 - "This study tested the hypothesis that aggregation of platelets and release of thromboxane A2 at the site of a coronary arterial stenosis may contribute to myocardial ischemia by impairing flow regulation of the distal coronary bed. " 11/01/1986 - "These data suggest that the thromboxane A2/PGH2 receptor antagonists, SQ29,548 and SQ28,688, inhibit cyclic reductions in coronary blood flow in this model by preventing the accumulation of platelets at the site of a critical coronary arterial stenosis. " 06/01/2000 - "This exercise-induced vasoconstriction has been associated with the occurrence of myocardial ischemia and has been believed to be the result of endothelial dysfunction, with a reduced release or production of EDRF, increased sympathetic stimulation, enhanced platelet aggregation with release of thromboxane A2 and serotonin, or a passive collapse of the disease-free wall segment within the stenosis (the Bernoulli effect), or a combination of any of these. "
4.	Stroke (Strokes) 09/01/2014 - "N2 ameliorates neural injury during experimental ischemic stroke via the regulation of thromboxane A2 production." 09/01/2014 - "Thromboxane A2 (TXA2) promotes ischemic stroke injury and has strong effects in vascular contraction and vascular endothelial cell dysfunction. " 04/01/2014 - "Thromboxane A2 (TXA2) induces platelet aggregation and vasoconstriction, and agents that inhibit TXA2 production or interaction with receptors may exert potential application in stroke therapy. " 09/01/1988 - "Our results support a possible role for thromboxane A2 in the elevation of blood pressure in SHRSP but do not support a possible role for the prevention of stroke by thromboxane A2 synthase inhibition in these rats." 09/01/1988 - "Thromboxane A2 in severe hypertension and stroke in stroke-prone spontaneously hypertensive rats."
5.	Myocardial Ischemia (Ischemic Heart Diseases) 12/01/2008 - "Myocardial ischemia-mediated excitatory reflexes: a new function for thromboxane A2?" 08/01/1989 - "Increased Ca2+ influx into platelets induced by thromboxane A2 analog in patients with ischemic heart disease." 11/01/1987 - "Thromboxane A2 (TxA2) production increases significantly during acute myocardial ischemia. " 01/01/1986 - "Potentiation of thromboxane A2 release might contribute to myocardial ischemia associated with platelet activation." 12/01/1985 - "Thromboxane A2 (TxA2) production increases significantly during acute myocardial ischemia. "

Related Drugs and Biologics

1.	Epoprostenol (Prostacyclin)
2.	Serotonin (5 Hydroxytryptamine)
3.	Aspirin (Acetylsalicylic Acid)
4.	Leukotriene B4
5.	KW 3635
6.	Arachidonic Acid (Vitamin F)
7.	Prostaglandin H2 (PGH(2))
8.	Thromboxane-A Synthase
9.	Sodium
10.	Tissue Plasminogen Activator (Alteplase)

Related Therapies and Procedures

1.	Blood Component Removal (Apheresis)
2.	Transplants (Transplant)
3.	Intravenous Infusions
4.	Surgical Instruments (Clip)
5.	Hepatectomy